1-Palmitoyl-2-(13-hydroxy-cis-9,trans-11-octadecadienoyl)-L-3-phosphatidylcholine 1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC is an oxidized phospholipid that contains palmitic acid and 13(S)-HODE at the sn-1 and sn-2 positions, respectively
They may increase vulnerability in sensitive individuals, so closer monitoring is recommended
Autoimmune diseases and protein homeostasis Autoimmune diseases emerge from a catastrophic failure of immune tolerance, where the bodys defense system misidentifies its own cells as threats, leading to relentless inflammation and self-destruction
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release